Clinical trial
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
NCT00123851 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00123851 |
|---|---|
| Title | Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer |
| Official title | A Phase II Study of OSI-774 (Tarceva) in Combination With Oxaliplatin and Capecitabine in Previously Treated Patients With Stage IV Colorectal Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Sanofi-Synthelabo Industry OSI Pharmaceuticals Hoffmann-La Roche Genentech, Inc. Massachusetts General Hospital Beth Israel Deaconess Medical Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Tarceva (OSI-774), Capecitabine, Oxaliplatin |
| Enrollment | 32 |
| Start date | Mar 1, 2003 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Jul 26, 2005 |
| Last update posted | Apr 28, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: